Elsevier

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Elsevier #Research and development #Survey

Report says many R&D companies have based decisions on flawed data

R&D teams are confident in their evidence, yet report making decisions based on flawed or incomplete data, according to Elsevier’s Corporate R&D of the Future report.  The report is based on a global survey of more than 1,000 R&D leaders, managers and researchers at R&D-led corporations. … Read More

#Editor's Choice #News

#Artificial intelligence (AI) #Collaboration #Drug discovery #Elsevier #Iktos #Partnership

Elsevier and Iktos launch AI-powered drug discovery database

Elsevier and Iktos have partnered to strengthen Elsevier’s chemistry solution, Reaxys, by combining the company’s chemistry data with synthetic planning AI technologies developed by Iktos. The partnership aims to support R&D organisations to decrease the time required to complete Design-Make-Test-Analyse cycles of small molecules, thus reducing… Read More

#Business & Investment #News

2024 predictions, road forward
#2024 predictions #AI / data analytics / healthtech / informatics #Antiverse #Artificial intelligence (AI) #Drug discovery #Elsevier #Enhanc3D Genomics #IQVIA #Lab automation #Machine learning #Medidata #Ori Biotech #Technology #TrakCel #Trinity Life Sciences

2024 predictions: Experts comment on AI, ML and automation

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes. Here, experts weigh in on the impact of artificial intelligence (AI), machine learning (ML) and automation in… Read More

#Exclusive Content #Opinion #Trends & Analysis